AGEN Agenus Inc.
USHealthcareAs of 2026-07-08 16:00
Why AGEN matters now
Agenus Inc. (AGEN) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.25 with -7.14% on the session and $135.3M in market capitalization; recent performance reads 1-month -2.91% and YTD -4.46%.
The latest financial table shown here is Q1 2026, with revenue of $33.7M, net income of $39.2M, and EPS of $1.02. Investors can compare that operating picture with valuation signals such as P/E 1322.24 and FCF yield -70.1%.
The latest indexable market news headline is "Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00; recent insider activity includes ARMEN GARO H filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
1322.24
PEG
13.22
P/B
-0.51
P/S
1.01
EV/EBITDA
3.10
DCF Value
$-24.12
FCF Yield
-70.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.1%
Operating Margin
6.6%
Net Margin
52.2%
ROE
-23.1%
ROA
34.6%
ROIC
10.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $33.7M | $39.2M | $1.02 |
| Q4 2025 | $34.2M | $-10.6M | $-0.30 |
| FY 2025 | $114.2M | $115.0K | $-0.00 |
| Q3 2025 | $30.2M | $63.9M | $1.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.33
Target (Median)
$7.00
Target Range
$7.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.54
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.